Update on SAATELLITE: Phase 2 trial for prevention of *S. aureus* pneumonia in mechanically ventilated patients

Bruno FRANÇOIS & Hasan JAFRI

ECCMID

Amsterdam, 10th April 2016

Study Background

- *S. aureus* colonization rate in intubated patients in ICU: 22-39% (Sirvent 2000; Ewig 1999; Honda 2010)
- Rate of *S. aureus* VAP among colonized intubated patients: up to 35% (Sivent 2000; Ewig 1999)
  - Enriched, colonized individuals with 60% VAP in anti-pseudomonas mAb study (François 2012)
    - 50% Relative Reduction in VAP among active arm (vs. placebo) for a mAb (François 2012)
  - Ventilator associated tracheobronchitis (VAT) progression to VAP: 47-60% (Nseir 2008; Palmer 2008)

Protocol objectives

- Primary
  - To evaluate the effect of MEDI4893 in reducing the incidence of *S aureus* pneumonia
  - To evaluate the safety of a single IV dose of MEDI4893
- Secondary
  - To evaluate the serum pharmacokinetics (PK) of MEDI4893
  - To evaluate the serum anti-drug antibody (ADA) responses to MEDI4893
  - To evaluate the effect of MEDI4893 in reducing the incidence of *S aureus* pneumonia by mechanical ventilation status

Study Design



Investigational product administration, single IV dose

Interim PK analysis

Stage 1 analysis: Efficacy, PK, and safety

Stage 2 analysis: Long-term safety follow-up

Treatment Groups

Total N = 462, (blinded sample size re-estimation after 33% to 40% enrolled)

Randomized 1:1:1

- Low-Dose MEDI4893 (n = 154)
- High-Dose MEDI4893 (n = 154)
- Placebo (n = 154)

Key Eligibility Criteria

- Age 18 years or older at the time of study entry
- Currently intubated, on mechanical ventilation in ICU
- Expected to remain intubated and mechanically ventilated for > 3 days based on investigator estimate
- Tracheal or bronchial sample positive for *S aureus* within 36 hours prior to randomisation
- No diagnosis of new-onset pneumonia within 72 hours prior to randomization

Rapid Diagnostic for Patient Enrichment

Cepheid S. aureus MSSA/MRSA PCR Test

Integrated Platform and Test

Insert Swab into Elution Reagent Vial and Break at Score

1

Vortex and Dispense Sample into Port S

2

Sample automatically filtered and washed

DNA mixed with dry PCR reagents

Insert Cartridge and Start Assay

3

Real-time amplification and detection in integrated reaction tube



Results in less than 75 minutes

4

Total Hands-On Time <2 minutes
Time to result <75 minutes

SAATELLITE Sites

- Belgium: 11
- Spain: 10
- France: 18
- Germany: 11
- Cz Rep: 9
- Hungary: 4
- Switzerland: 3
- Greece: 7
- UK: 4

Selected

Activated

Current* Study Enrollment

- **225 subjects enrolled**
- **76 subjects randomized and dosed**
  - 46 subjects in France
  - 13 subjects in Belgium
  - 9 subject in Switzerland
  - 7 subjects in Spain
  - 1 subject in Greece

*April 5, 2016

SAATELLITE To Date

- True academic involvement in trial management
- Boards involving COMBACTE partners
- Overall interaction excellent despite new model and numerous different players
- Study progressing and making gains in a challenging study population, still seeking motivated and productive sites